Concord, which is backed by Quadria Capital Fund and Rakesh Jhunjhunwala's Rare Enterprises, is one of the leading global manufacturers of select fermentation-based APIs (F-APIs) across immunosuppressants and oncology with a market share of over 20% by volume in 2022.
